Mitsutoshi Matsuo
Overview
Explore the profile of Mitsutoshi Matsuo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
431
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Minami S, Okada K, Matsuo M, Kamohara Y, Sakamoto I, Kanematsu T
J Gastroenterol
. 2007 Feb;
42(1):91-5.
PMID: 17323000
Although stomal varices are a rare complication, bleeding stomal varices often need to be treated owing to symptoms of hypovolemic shock, recurrence of stomal bleeding, or deterioration in the quality...
12.
Nishikawa H, Sato E, Briones G, Chen L, Matsuo M, Nagata Y, et al.
J Clin Invest
. 2006 Jun;
116(7):1946-54.
PMID: 16794737
Bacterial vectors may offer many advantages over other antigen delivery systems for cancer vaccines. We engineered a Salmonella typhimurium vaccine strain to deliver the NY-ESO-1 tumor antigen (S. typhimurium-NY-ESO-1) through...
13.
Minami S, Okada K, Matsuo M, Hayashi T, Kanematsu T
J Gastrointest Surg
. 2005 Sep;
9(7):1006-8.
PMID: 16137598
No abstract available.
14.
Matsuo M, Nagata Y, Sato E, Atanackovic D, Valmori D, Chen Y, et al.
Proc Natl Acad Sci U S A
. 2004 Sep;
101(40):14467-72.
PMID: 15383663
We compared monocyte-derived dendritic cells and transforming growth factor-beta1-induced Langerhans-like cells (LCs) for their capacity to cross-present exogenous NY-ESO-1 protein/antibody immune complexes to an NY-ESO-1-specific CD8+ T cell clone. In...
15.
Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee S, et al.
Eur J Immunol
. 2004 Sep;
34(10):2919-29.
PMID: 15368308
NY-ESO-1 is a germ cell antigen aberrantly expressed by different tumor types that elicits strong humoral and cellular immune responses, representing one of the most promising candidates for vaccination of...
16.
Atanackovic D, Altorki N, Stockert E, Williamson B, Jungbluth A, Ritter E, et al.
J Immunol
. 2004 Feb;
172(5):3289-96.
PMID: 14978137
MAGE-3 is the most commonly expressed cancer testis Ag and thus represents a prime target for cancer vaccines, despite infrequent natural occurrence of MAGE-3-specific immune responses in vivo. We report...
17.
Atanackovic D, Matsuo M, Ritter E, Mazzara G, Ritter G, Jager E, et al.
J Immunol Methods
. 2003 Sep;
278(1-2):57-66.
PMID: 12957396
CD4+ T cells play an important role in the induction and maintenance of an effective antiviral and antitumor immune response. However, standardized monitoring of antigen-specific CD4+ T cells has not...
18.
Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki N, et al.
Proc Natl Acad Sci U S A
. 2003 Jul;
100(15):8862-7.
PMID: 12853579
NY-ESO-1 is one of the most immunogenic proteins described in human cancers, based on its capacity to elicit simultaneous antibody and CD8+ T cell responses in vivo. Although HLA class...
19.
Gnjatic S, Atanackovic D, Matsuo M, Jager E, Lee S, Valmori D, et al.
J Immunol
. 2003 Jan;
170(3):1191-6.
PMID: 12538675
NY-ESO-1, a germ cell Ag often detected in tumor tissues, frequently elicits Ab and CD8(+) T cell responses in cancer patients. Overlapping long peptides spanning the NY-ESO-1 sequence have been...
20.
Gnjatic S, Jager E, Chen W, Altorki N, Matsuo M, Lee S, et al.
Proc Natl Acad Sci U S A
. 2002 Aug;
99(18):11813-8.
PMID: 12186971
NY-ESO-1 is a germ cell antigen aberrantly expressed in different tumor types that elicits strong humoral and cellular immune responses in cancer patients. Monitoring spontaneous CD8(+) T cell responses against...